IA
BDTX icon

IFP Advisors’s Black Diamond Therapeutics BDTX Stock Holding History

IFP Advisors’s Portfolio BDTX Stock Details BDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Hold
0
– – – 4149
2024
Q4 		– Hold
0
– – – 4378
2024
Q1 		– Sell
-300
Closed -$843 – 3123
2023
Q4 		$843 Hold
300
– – ﹤0.01% 2830
2023
Q3 		$861 Buy
+300
New +$1.1K ﹤0.01% 3029

Other funds holding BDTX

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

IFP Advisors's BDTX Position: Q1 2025 in Review

IFP Advisors held its Black Diamond Therapeutics (BDTX) position steady in Q1 2025 at 0 shares worth $22. The position accounts for ﹤0.01% of the portfolio, ranked #4149.

IFP Advisors first reported a position in BDTX in Q3 2023 and has held it in 2 quarters since. The position peaked at $861 in Q3 2023. 84 funds tracked by Wall St. Rank hold BDTX as of Q1 2025.

  • IFP Advisors held 0 shares of Black Diamond Therapeutics worth $22 as of Q1 2025.
  • IFP Advisors left its Black Diamond Therapeutics share count unchanged in Q1 2025.
  • Black Diamond Therapeutics made up ﹤0.01% of IFP Advisors's portfolio in Q1 2025, its #4149 holding.
  • IFP Advisors first reported a position in Black Diamond Therapeutics in Q3 2023 and has held it in 2 quarters since.
  • IFP Advisors's Black Diamond Therapeutics position peaked at $861 in Q3 2023.
  • 84 funds tracked by Wall St. Rank held Black Diamond Therapeutics as of Q1 2025.

Based on IFP Advisors's 13F filing for Q1 2025, filed 5 May 2025.